Sugi Predict

Sugi Predict / Compounds / SCHEMBL3204846

SCHEMBL3204846

SCHEMBL3204846

COc1ccc(NC(=O)Nc2cc(F)cc(CCCN3CCN(C(=O)O)CC3)c2)cn1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.47
▸ KMT2A Q03164 6/20 0.47
▸ PABPC1 P11940 4/20 0.47
▸ NPC1 O15118 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ FPR3 P25089 1/20 0.41
▸ FPR2 P25090 1/20 0.41
▸ EPHX2 P34913 2/20 0.41
▸ POLB P06746 1/20 0.40
▸ HTR2A P28223 3/20 0.40
▸ HTR2C P28335 2/20 0.40
▸ LMNA P02545 2/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39
▸ FAAH O00519 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400040 0.93 MEN1 (0.47) MEN1KMT2APABPC1NPC1MAPT
SCHEMBL400961 0.93 MEN1 (0.47) MEN1KMT2APABPC1NPC1MAPT
SCHEMBL3210124 0.88 HTR1A (0.45) FPR3FPR2EPHX2FAAH
SCHEMBL400383 0.88 KMT2A (0.45) MEN1KMT2APABPC1NPC1MAPT
SCHEMBL23573834 0.84 PIK3CA (0.45) MAPTFPR3FPR2EPHX2HTR2A
SCHEMBL401663 0.83 HTR1A (0.42) MAPTFPR3FPR2EPHX2HTR2A
SCHEMBL3208943 0.83 HTR1A (0.50) HTR2AHTR2C
SCHEMBL3188068 0.82 HTR1A (0.55) MEN1KMT2ANPC1MAPTEPHX2
SCHEMBL545635 0.81 HTR1A (0.43) FPR3FPR2EPHX2POLB
SCHEMBL402570 0.81 HRH2 (0.46) MEN1KMT2AMAPTHTR2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-10035770-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2018-07-31 — — US disclosed
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2017-09-21 — — US disclosed
US-9643925-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2017-05-09 — — US disclosed
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2016-04-28 — — US disclosed
US-9150564-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2015-10-06 — — US disclosed
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure CYTOKINETICS, INC. 2012-07-05 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172372-A1 Ureas and Their Use in the Treatment of Heart Failure TNNI3, TNNT2, MYLK2 MEN1 4505/4885KMT2A 3674/4885PABPC1 3069/4885
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MEN1 4319/4885KMT2A 4052/4885PABPC1 2199/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 MEN1 4745/4885KMT2A 2999/4885PABPC1 1282/4885
US-20170267638-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MEN1 4319/4885KMT2A 4052/4885PABPC1 2199/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 MEN1 4493/4885KMT2A 4149/4885PABPC1 1234/4885
US-20160115133-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-10035770-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 MEN1 4319/4885KMT2A 4052/4885PABPC1 2199/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MEN1 4344/4885KMT2A 4396/4885PABPC1 2166/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 MEN1 4493/4885KMT2A 4149/4885PABPC1 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.